Geron Corporation, a commercial stage biopharmaceutical company, has announced the issuance of equity awards to six newly hired employees as part of their compensation package. The awards include stock options for 274,000 shares and restricted stock units (RSUs) for 137,000 shares, totalling an aggregate of 411,000 shares of common stock. Granted on May 16, 2025, the stock options are priced at $1.27 per share, reflecting the closing price on the grant date, and have a 10-year term with a vesting schedule that begins six months after the start of employment. The RSUs vest annually, with 25% of the award becoming available each year, tied to continued employment. These inducement grants were approved by Geron's Compensation Committee in line with Nasdaq Listing Rule 5635(c)(4) and fall under the company's 2018 Inducement Award Plan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.